Omnicell, Inc. (NASDAQ:OMCL) Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp decreased its holdings in Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 26.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 639,772 shares of the company's stock after selling 229,562 shares during the period. Bank of New York Mellon Corp owned about 1.38% of Omnicell worth $28,483,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. Van ECK Associates Corp lifted its position in Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company's stock valued at $44,000 after acquiring an additional 315 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company's stock worth $59,000 after purchasing an additional 355 shares in the last quarter. KBC Group NV lifted its holdings in shares of Omnicell by 60.8% during the 4th quarter. KBC Group NV now owns 2,057 shares of the company's stock valued at $92,000 after purchasing an additional 778 shares during the last quarter. CIBC Asset Management Inc acquired a new stake in shares of Omnicell in the 4th quarter worth $201,000. Finally, Summit Global Investments purchased a new position in Omnicell during the 3rd quarter worth $221,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages recently commented on OMCL. Benchmark reaffirmed a "buy" rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. StockNews.com raised shares of Omnicell from a "hold" rating to a "buy" rating in a report on Thursday, March 6th. Bank of America dropped their price objective on shares of Omnicell from $54.00 to $46.00 and set a "neutral" rating on the stock in a report on Monday, January 6th. JPMorgan Chase & Co. raised their target price on Omnicell from $37.00 to $44.00 and gave the stock a "neutral" rating in a research note on Thursday, November 21st. Finally, Wells Fargo & Company dropped their price target on Omnicell from $49.00 to $40.00 and set an "equal weight" rating on the stock in a research note on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $52.33.

Remove Ads

Omnicell Stock Performance

OMCL stock traded down $2.36 during trading on Wednesday, hitting $33.35. 798,735 shares of the company traded hands, compared to its average volume of 492,515. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.37 and a quick ratio of 1.22. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.75. The stock's 50-day simple moving average is $41.42 and its 200 day simple moving average is $43.53. The company has a market cap of $1.56 billion, a PE ratio of 123.93, a P/E/G ratio of 7.53 and a beta of 0.85.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a net margin of 1.13% and a return on equity of 3.82%. On average, equities analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.